Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of HDM2012 in Subjects With Advanced Solid Tumors

NCT07100249 is registered in ClinicalTrials.gov with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07100249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07100249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of HDM2012 in Subjects With Advanced Solid Tumors
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
August 6, 2025
Completion date
June 30, 2028
Enrollment
129 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors